M echanical heart valve thrombosis with obstruc- tion is a relatively rare event. It has been reported with all types of mechanical valves currently in use and varies in annual incidence from 0.1% to 0.5%.' It is an important cause of progressive "blockages between the viscera" and therefore can result in breathlessness and death. 2 Mechanical valve thrombosis is often associated with poor control of oral anticoagulation and is probably one end of the spectrum of all thromboembolic complications seen in prosthetic heart valves. Mechanical and biological prostheses form thrombus, tissue growth or pannus, and calcium in typical locations: above the struts, below the sewing rings, and at functional or engineered hinge points. [3] [4] [5] These characteristic locations may be related to the unique flow patterns of each valve. 8 See p 30 Until recently, the standard therapy for progressive valve obstruction has been urgent or emergency valve rereplacement, which carried significant overall surgical morbidity and mortality of 4.5-25%.7-12 Surgical mortality increased from 2% to 4% in low-risk groups to 25-40% in high-risk groups. These high-risk subgroups included those with mitral (versus aortic) valve replacement, New York Heart Association functional class IV symptoms, emergency surgery, need for multiple procedures or long cross-clamp times, and increased age. It remains uncertain whether cinefluoroscopy or Doppler echocardiography is the optimal method to follow thrombolytic therapy. In this regard, premature discontinuation of thrombolytic or heparin therapy would presumably be manifested by early rethrombosis at follow-up. All of these patients had excellent clinical follow-up to determine early rethrombosis. Ten of 12 patients remained free from thromboembolic events for a mean follow-up of 17 months. In two patients, rethrombosis occurred after 6 and 8 months of follow-up, suggesting separate episodes of incomplete warfarin anticoagulation rather than incomplete thrombolysis. Therefore, the therapeutic endpoints described using cinefluoroscopy or Doppler echocardiography have both been associated with a minimal incidence of early rethrombosis.
Potential complications of thrombolytic therapy, including delay of definitive surgical treatment, should not be minimized. Thrombolytic therapy has been associated with embolism, fever, bleeding, and allergic reactions. Because patients with severe heart failure have the highest surgical mortality, they are an important group to consider for thrombolytic treatment. In such patients, however, the decision to treat with thrombolytics will delay and thus effectively preclude emergency surgery. are the relative risks of treating of various valves are badly needed. The optimal methods to follow the results of thrombolytic therapy will remain elusive for a long time because of the rarity of the event.
More than 4,000 years ago, the Emperor Huang Ti learned that recognizing and relieving obstructions in the circulation is a primary method of treating breathlessness and preventing death. Recent advances in thrombolytic therapy of coronary disease are practical applications of this lesson. The report of Silber et al and the many recent case reports are demonstrating that medical therapy of thrombosed mechanical heart valves is also becoming an accepted therapy in selected patients.
